Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
December 06, 2024 | 06:56
Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, Revenir™.
Mobile Version